Sign up to save your podcasts
Or
Share Robert Z. Orlowski, MD, PhD / Nina Shah, MD - The Multiple Myeloma Workshop: Exploring the Convergence of Novel Therapeutic Platforms, Cell Therapy, and ASCT
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Robert Z. Orlowski, MD, PhD / Nina Shah, MD - The Multiple Myeloma Workshop: Exploring the Convergence of Novel Therapeutic Platforms, Cell Therapy, and ASCT
Go online to PeerView.com/ATX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new multiple myeloma (MM) CME program, two leading myeloma experts discuss key questions and controversies arising from the rapid validation of novel therapeutics for patients with MM who are autologous stem cell transplantation (ASCT) eligible. Although the use of ASCT remains a core therapeutic modality for MM, using ASCT in conjunction with innovative treatment options—including CAR-T cell therapy, proteasome inhibitors, immunomodulators, and antibodies such as, CD38 antibodies, BCMA-targeting antibody-drug conjugates, and bispecific antibodies—can substantially improve outcomes. These improvements have been observed across the continuum of care, from primary therapy to the management of relapsed/refractory disease (post-ASCT), as well as in the setting of minimal residual disease eradication. Hear our expert panel as they highlight these improvements and discuss the integration of approved and emerging novel therapies in MM. Upon completion of this activity, participants should be better able to: List current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in various multiple myeloma treatment settings, Describe efficacy and safety data surrounding novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new targeted agent classes in the management of ASCT-eligible patients with multiple myeloma, Develop regimens with novel components for ASCT-eligible patients with multiple myeloma, including as induction/consolidation or maintenance therapy, or in the setting of early relapse or refractory myeloma.
View all episodes
By PVI, PeerView Institute for Medical Education
4.3
99 ratings
Go online to PeerView.com/ATX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new multiple myeloma (MM) CME program, two leading myeloma experts discuss key questions and controversies arising from the rapid validation of novel therapeutics for patients with MM who are autologous stem cell transplantation (ASCT) eligible. Although the use of ASCT remains a core therapeutic modality for MM, using ASCT in conjunction with innovative treatment options—including CAR-T cell therapy, proteasome inhibitors, immunomodulators, and antibodies such as, CD38 antibodies, BCMA-targeting antibody-drug conjugates, and bispecific antibodies—can substantially improve outcomes. These improvements have been observed across the continuum of care, from primary therapy to the management of relapsed/refractory disease (post-ASCT), as well as in the setting of minimal residual disease eradication. Hear our expert panel as they highlight these improvements and discuss the integration of approved and emerging novel therapies in MM. Upon completion of this activity, participants should be better able to: List current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in various multiple myeloma treatment settings, Describe efficacy and safety data surrounding novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new targeted agent classes in the management of ASCT-eligible patients with multiple myeloma, Develop regimens with novel components for ASCT-eligible patients with multiple myeloma, including as induction/consolidation or maintenance therapy, or in the setting of early relapse or refractory myeloma.
More shows like PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
View all
JAMA Editors' Summary
129 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
6 Listeners
Lung Cancer Update
31 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
10 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
28 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
9 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
3 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
5 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
NEJM This Week
317 Listeners
Journal of Clinical Oncology (JCO) Podcast
42 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
Research To Practice | Oncology Videos
115 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners
JAMA Clinical Reviews
486 Listeners
ASCO Daily News
55 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
21 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
321 Listeners
Oncology Today with Dr Neil Love
54 Listeners
CCO Oncology Podcast
10 Listeners
Two Onc Docs
166 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
38 Listeners